Free Trial

DexCom (DXCM) Competitors

DexCom logo
$68.20 -1.31 (-1.88%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$68.24 +0.04 (+0.06%)
As of 09/23/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DXCM vs. HQY, PODD, ABT, AMN, ITGR, BDX, IDXX, EW, RMD, and STE

Should you be buying DexCom stock or one of its competitors? The main competitors of DexCom include HealthEquity (HQY), Insulet (PODD), Abbott Laboratories (ABT), AMN Healthcare Services (AMN), Integer (ITGR), Becton, Dickinson and Company (BDX), IDEXX Laboratories (IDXX), Edwards Lifesciences (EW), ResMed (RMD), and STERIS (STE). These companies are all part of the "medical" sector.

DexCom vs. Its Competitors

DexCom (NASDAQ:DXCM) and HealthEquity (NASDAQ:HQY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

97.8% of DexCom shares are held by institutional investors. Comparatively, 99.6% of HealthEquity shares are held by institutional investors. 0.3% of DexCom shares are held by company insiders. Comparatively, 1.5% of HealthEquity shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DexCom has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, HealthEquity has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.

DexCom currently has a consensus target price of $99.89, indicating a potential upside of 46.47%. HealthEquity has a consensus target price of $119.77, indicating a potential upside of 27.62%. Given DexCom's higher probable upside, analysts plainly believe DexCom is more favorable than HealthEquity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DexCom
0 Sell rating(s)
5 Hold rating(s)
14 Buy rating(s)
3 Strong Buy rating(s)
2.91
HealthEquity
0 Sell rating(s)
1 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
3.00

In the previous week, DexCom had 21 more articles in the media than HealthEquity. MarketBeat recorded 30 mentions for DexCom and 9 mentions for HealthEquity. HealthEquity's average media sentiment score of 1.30 beat DexCom's score of 0.90 indicating that HealthEquity is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DexCom
16 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
HealthEquity
7 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DexCom has a net margin of 13.29% compared to HealthEquity's net margin of 11.49%. DexCom's return on equity of 30.41% beat HealthEquity's return on equity.

Company Net Margins Return on Equity Return on Assets
DexCom13.29% 30.41% 10.08%
HealthEquity 11.49%12.04%7.44%

DexCom has higher revenue and earnings than HealthEquity. DexCom is trading at a lower price-to-earnings ratio than HealthEquity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DexCom$4.30B6.22$576.20M$1.4447.36
HealthEquity$1.20B6.74$96.70M$1.6556.88

Summary

DexCom beats HealthEquity on 10 of the 17 factors compared between the two stocks.

Get DexCom News Delivered to You Automatically

Sign up to receive the latest news and ratings for DXCM and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DXCM vs. The Competition

MetricDexComMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$27.26B$6.83B$5.76B$10.51B
Dividend YieldN/A1.20%5.53%4.57%
P/E Ratio47.3625.7676.4326.62
Price / Sales6.22194.61473.6992.75
Price / Cash30.9321.9037.4661.85
Price / Book12.685.0513.616.45
Net Income$576.20M$178.07M$3.29B$271.57M
7 Day Performance-10.78%2.19%1.87%2.61%
1 Month Performance-17.09%6.81%4.03%7.28%
1 Year Performance-0.67%23.10%77.41%29.60%

DexCom Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DXCM
DexCom
4.9748 of 5 stars
$68.20
-1.9%
$99.89
+46.5%
-2.2%$27.26B$4.30B47.3610,300
HQY
HealthEquity
4.3698 of 5 stars
$93.02
+0.6%
$119.77
+28.8%
+18.5%$8.01B$1.20B56.383,120Positive News
Insider Trade
PODD
Insulet
4.6049 of 5 stars
$340.29
-0.4%
$335.12
-1.5%
+37.2%$23.95B$2.07B103.433,900
ABT
Abbott Laboratories
4.94 of 5 stars
$131.40
-1.7%
$144.47
+9.9%
+18.3%$228.70B$41.95B16.47114,000Positive News
Dividend Announcement
AMN
AMN Healthcare Services
4.7449 of 5 stars
$18.21
-0.2%
$23.25
+27.7%
-58.5%$697.62M$2.98B-2.342,968
ITGR
Integer
3.9355 of 5 stars
$100.11
-1.2%
$140.25
+40.1%
-19.6%$3.51B$1.79B44.1011,000Positive News
BDX
Becton, Dickinson and Company
4.9608 of 5 stars
$185.90
-0.5%
$211.44
+13.7%
-20.6%$53.29B$21.39B33.4474,000Positive News
IDXX
IDEXX Laboratories
4.1402 of 5 stars
$643.99
+0.4%
$649.44
+0.8%
+27.7%$51.52B$4.04B53.6211,000Positive News
EW
Edwards Lifesciences
4.7356 of 5 stars
$76.10
-1.9%
$86.26
+13.4%
+10.8%$44.68B$5.44B10.9515,800Positive News
Analyst Upgrade
RMD
ResMed
4.6726 of 5 stars
$271.39
+0.5%
$278.36
+2.6%
+12.0%$39.74B$5.15B28.5410,600Positive News
STE
STERIS
4.8865 of 5 stars
$247.71
-0.9%
$273.50
+10.4%
+4.1%$24.40B$5.46B37.9317,787

Related Companies and Tools


This page (NASDAQ:DXCM) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners